Boehringer Ingelheim Initiates Phase IIa Study in NASH - Interview with Pharmaxis Chief Executive Officer
Release Date: 25/08/2017 9:00am
Pharmaceutical research company Pharmaxis (ASX: PXS) today released a video interview with Chief Executive Officer Gary Phillips following the joint announcement with Boehringer Ingelheim that it has initiated a Phase 2a study in the fatty liver disease NASH, triggering the payment of an €18 million (A$27M) milestone to Pharmaxis.
The five minute video interview can be accessed via the following link:
Categories: Video Content